# Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise

> **NCT04292535** · PHASE2 · COMPLETED · sponsor: **Michigan State University** · enrollment: 116 (actual)

## Conditions studied

- Insulin
- Exercise

## Interventions

- **DRUG:** Placebo into the intranasal mucosa
- **DRUG:** 20 IU NovoLog Insulin aspart into the intranasal mucosa
- **DRUG:** 40 IU NovoLog Insulin aspart into the intranasal mucosa
- **DRUG:** 60 IU NovoLog Insulin aspart into the intranasal mucosa
- **DRUG:** 80 IU NovoLog Insulin aspart into the intranasal mucosa
- **DRUG:** 100 IU NovoLog Insulin aspart into the intranasal mucosa
- **DRUG:** 120 IU NovoLog Insulin aspart into the intranasal mucosa

## Key facts

- **NCT ID:** NCT04292535
- **Lead sponsor:** Michigan State University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-15
- **Primary completion:** 2020-02-20
- **Final completion:** 2020-02-20
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2021-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04292535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04292535, "Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04292535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*